ClinVar Miner

Submissions for variant NM_000053.3(ATP7B):c.388_389dupGC (p.Ala131Glnfs) (rs1057517384)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000409526 SCV000487200 likely pathogenic Wilson disease 2016-10-24 criteria provided, single submitter clinical testing
GeneDx RCV000489522 SCV000577513 pathogenic not provided 2017-03-27 criteria provided, single submitter clinical testing The c.388_389dupGC variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The c.388_389dupGC variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The c.388_389dupGC variant causes a frameshift starting with codon Alanine 131, changes this amino acid to a Glutamine residue and creates a premature Stop codon at position 23 of the new reading frame, denoted p.Ala131GlnfsX23. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. In summary, we interpret c.388_389dupGC as a pathogenic variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.